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Abstract Nearly 50 % of colorectal cancer (CRC)
patients develop liver metastases with liver resection being
the only option to cure patients. Residual micrometastases
or circulating tumor cells are considered a cause of tumor
relapse. This work investigates the influence of partial
hepatectomy (PH) on the growth and molecular composi-
tion of CRC liver metastasis in a syngeneic rat model. One
million CC531 colorectal tumor cells were implanted via
the portal vein in WAG/Rij rats followed by a 30 % PH a
day later. Control groups either received tumor cells fol-
lowed by a sham-operation or were injected with a buffer
solution followed by PH. Animals were examined with
magnetic resonance imaging (MRI) and liver tissues were
processed for immunolabeling and PCR analysis. One-third
PH was associated with an almost threefold increase in
relative tumor mass (MRI volumetry: 2.8-fold and tran-
script levels of CD44: 2.3-fold). Expression of molecular
markers for invasiveness and aggressiveness (CD49f,
CXCR4, Axin2 and c-met) was increased following PH,
however with no significant differences when referring to
the relative expression levels (relating to tumor mass).
Liver metastases demonstrated a significantly higher pro-
liferation rate (Ki67) 2 weeks following PH and cell divi-
sions also increased in the surrounding liver tissue.
Following PH, the stimulated growth of metastases clearly
exceeded the compensation in liver volume with long-
lasting proliferative effects. However, the distinct tumor
composition was not influenced by liver regeneration.
Future investigations should focus on the inhibition of cell
cycle (i.e. systemic therapy strategies, irradiation) to hinder
liver regeneration and therefore restrain tumor growth.
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Introduction
The liver is one of few organs with the capability of
regenerating fully in capacity and function. Currently,
partial hepatectomy (PH) is an effective means of curing
patients from various lesions of this organ within the
clinical setting of a multimodal approach [1]. Furthermore,
surgery has unavoidably been drawn into having to
understand the process of liver regeneration. For over
60 years, PH has been performed to resect liver primaries
such as hepatocellular carcinoma or liver metastasis and
with time, metastatic disease became the most frequent
indication for partial liver resection [2].
Colorectal cancer (CRC) is the third most common
cancer in the Western world [3], and the second leading
cause of death in both genders; nearly half of all affected
patients develop liver metastasis [4]. The prevalence is
around 15–30 % in newly diagnosed cases [5], and an
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additional 25 % of cases eventually develop metastasis
within 2 years. Despite the resection of tumor-affected
lobes, the 5-year survival still borders on 30 % [6].
Following resection of the primary, systemic minimal
residual disease can remain asymptomatic for periods that
can last years or even decades. This is due to the presence
of disseminated tumor cells in different organs. In partic-
ular, several cancers including melanoma, breast, prostate,
and colorectal carcinoma undergo dormant periods before
metastatic recurrence [7]. This metastatic rebirth may be
initiated by an imbalance of various factors or mechanisms
contributing to cellular changes shifting apoptosis towards
proliferation (e.g. release of proliferative factors by the
micro-environment), by an increase in angiogenesis or
evasion of the immune system [8]. These three conditions
have to be considered when tumors are re-initiated as
metastases in secondary sites such as the liver. However,
metastatic relapses following curative resection of hepatic
metastases may principally originate from residual and
undetectable micrometastasis in the remaining liver
parenchyma or circulating single tumor cells rather than
dormant tumor cells. In this context, PH may trigger a
myriad of proliferative signals that provoke the prolifera-
tion of residual or circulating cancer cells, which are
consequently stimulated into fast and novel tumor forma-
tion. In humans, metastatic disease (intrahepatic or extra-
hepatic) usually re-occurs within 36 months following
hepatic R0 resection. Moreover, recurrence-free survival in
patients following PH is 10.6 months in former bilobar and
16.1 months in unilobar manifestations of CRC liver
metastasis [9]. Despite these sobering observations, even in
advanced stages of CRC disease and various concepts of
systemic therapy, liver resection remains quintessential to
the successful treatment of patients and we will certainly
have to look into new strategies as to how to modify
(reduce) the regenerative response following PH at some
stage in the future to improve patient prognosis.
Our workgroup reported on a complex culture system
capable of mimicking the micromilieu of the regenerating
liver in vitro [10]. We incubated primary mature rat
hepatocytes in this liver-specific growth medium (supple-
mented with mitogens and conditioned media derived from
hepatocytes and stromal cell culture supernatants). These
adult liver cells were subsequently stimulated into prolif-
eration. Aiming to investigate the underlying mechanisms
and factors by which liver regeneration may trigger the
growth of tumor cells, we employed the same culture
system and conditions. And indeed, we observed that CRC
cells (rat cell line CC531) were stimulated into rapid
expansion and significantly higher proliferation in this
growth medium than that noted in control media (RPMI
plus 2 % FCS) (unpublished data). With these encouraging
results in mind, we then investigated the growth of tumor
cells in a preclinical rat animal model of orthotopic CRC
liver metastasis. We therefore implemented and modified
an experimental rat model, in which CC531 tumor cells
were implanted into syngeneic WAG/Rij rats [11]. Refer-
ring to frequent mutations in human CRC, the rat cell line
CC531 is also known to display a prototypic beta-catenin
(Ctnnb1) mutation (Thr(41)Ile) as well as a ki-ras (G12D)
mutation, providing unambiguous evidence of the consti-
tutive activation of these pathways [12]. The injection of
these tumor cells via the portal vein leads to the repro-
ducible formation of liver metastases and therefore reflects
the human, weakly immunogenic, tumor-host relationship
well and thus provides an excellent opportunity to study
tumor cell growth under the influence of PH.
In the present study, we hypothesize that liver regenera-
tion triggers a course of molecular signaling and the sub-
sequent activation of pathways which accentuate the
proliferation of tumor cells and finally lead to the increased
formation of metastasis in the liver parenchyma. We
investigated the metastatic ability and behavior (for exam-
ple: spatial growth and expansion, expression of molecular
features as well as markers of invasiveness and proliferative
effects both on the metastases as well as on the surrounding
liver tissue). We were particularly interested in quantifying
the tumor burden and identifying molecular pathways which
mediate and/or enhance the tumor spread following PH.
Materials and methods
Animals and reagents
Male WAG/Rij rats (weight 160–200 g) were purchased from
Charles River (Sulzfeld, Germany). Animals were kept on
12-hour day/night rhythm and fed with a standard rat diet
(ssniff, Soest, Germany). All animal breeding, care and
experimentation procedures were in accordance with the
German national and regional legislation on animal protection.
Unless specified otherwise, all chemicals and reagents
were supplied by Sigma-Aldrich (Deisenhofen, Germany).
Fetal calf serum (FCS) was purchased from PAN (Aidenbach,
Germany) and trypsin 10-fold was supplied by PAA (Pas-
ching, Austria). Primary antibodies were purchased and used
as illustrated in Table 1. Secondary fluorescence labeling
antibodies (Alexa Fluor) were obtained from Molecular
Probes (Goettingen, Germany). Tumor cells CC531 were
supplied by CLS (Eppelheim, Germany) and cultured in
75 cm2 cell flasks (Sarstedt, Nuembrecht, Germany).
Cell culture
CRC cells from the rat cell line CC531 were expanded and
stored in frozen aliquots (-70 C). After thawing, the cells
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were routinely cultured on 75 cm2 culture flasks in RPMI
1640, supplemented with 10 % FCS, 1 % L-glutamine and
1 % penicillin/streptomycin at 37 C and 5 % CO2 in a
humidified incubator. After initial seeding, FCS concen-
tration was reduced to 5 % with the first medium change.
Tumor cells were passaged once (following 3 days in
culture), cultured for a further 4 days, and then trypsinized
for subsequent implantation studies. Tumor cells from the
same passage were used for all the implantation
experiments.
Animal procedures
In the first step, the stable and reproducible growth of liver
metastases as well as phenotypic marker expression was
documented following tumor cell implantation. Animals
were anesthetized under constant sevofluran inhalation
(Sevorane, Abbott, Wiesbaden, Germany) following
subcutaneous application of carprofen (Rimadyl, Pfizer,
Berlin, Germany) (5 mg/kg body weight). After median
laparotomy, the hilum of the liver was exposed to access
the portal vein. One million tumor cells in a volume of
250 ll PBS buffer were injected slowly into the portal vein
using a 28 G needle. Animals were sacrificed after 3 days,
1 and 2 weeks. Tissue samples from the liver were excised,
snap-frozen for PCR-analysis, frozen in 2-methylbutane at
-70 C for fluorescence immunolabeling or processed for
paraffin embedding.
After successful establishment of the rat model for CRC
liver metastases, we investigated the effects of PH on
tumor cell growth. For this purpose, animals were divided
into three groups:
Group 1: Tumor cell implantation ? 30 % PH (inter-
vention)
Group 2: Tumor cell implantation ? mobilization of
liver (sham-OP)
Group 3: Injection of buffer solution ? PH (control)
Group 1 received an implantation of tumor cells via the
portal vein as described above. Twenty-four hours later,
re-laparotomy was performed to expose the lateral segment
of the left liver lobule, which was removed by central
ligation. The laparotomy incision was closed by continuous
suture. In Group 2, animals were injected with tumor cells,
re-laparotomy being performed 24 h later comprising
gentle mobilization of the lateral segment of the left liver
lobule. Animals from Group 3 received an injection of
buffer solution and underwent PH a day later. Animal
experiments were terminated at the latest 2 weeks after
tumor cell implantation. Explanted livers were sliced for
macroscopic assessment and photographic documentation
of the section planes. Thereafter, tissue samples were
processed and stored as described above.
Immunolabeling
Cryostat sections (5 lm) were fixed in ice-cold acetone for
10 min, or paraformaldehyde at room temperature (RT) for
30 min, followed by 70 % ethanol at -20 C for another
30 min and were finally stored at -80 C. After rehydra-
tion in Tris/HCl buffer (pH 7.6), sections were immuno-
stained for the first antigen (incubation with the first
primary antibody anti-CD44 overnight at 4 C) and further
processed with the second primary antibody anti-Connexin
32 (Cx32), anti-CD49f or anti-frizzled. Single staining
procedures were performed with anti-signal transducer and
activator of transcription 3 (STAT3) and anti-b-catenin.
The secondary antibodies Alexa Fluor 555 goat anti-mouse
IgG and species-specific Alexa Fluor 488 or 568 IgG
(1:400, 1 h at RT) were used for fluorescence visualization.
Negative controls were carried out for each antibody by
omitting the primary antibody from the protocol. Samples
were covered with 50 ll Mowiol 4-88 based mounting
medium (Calbiochem, Darmstadt) containing 1.6 ll DAPI/
ml and evaluated under a microscope (LEICA DM IRE2,
Bensheim, Germany).
Endogenous peroxidase was inactivated on paraffin
sections (2 lm) by incubation with 3 % H2O2 in 100 %
methanol for 30 min at RT. The sections were further
exposed to the primary antibodies anti-CD44 or anti-Ki67
Table 1 Antibodies for co-localization studies
Antibody Species Manufacturer Dilution
CD44 Mouse monoclonal IgG2a, clone ox-49 BD Pharmingen, Heidelberg, Germany 1:500
Cx32 (gap junction protein) Rabbit, polyclonal Sigma, Saint Louis, MO, USA 1:5,000
Frizzled (wnt-receptor) Goat, polyclonal R & D Systems, Wiesbaden, Germany 1:50
CD49f Mouse monoclonal IgG1, clone Mab-5A Acris, Herford, Germany 1:200
Phospho-STAT3 (Tyr705) Rabbit polyclonal Cell Signaling, Danvers, MA, USA 1:50
b-Catenin Rabbit polyclonal BD Bioscience, Heidelberg, Germany 1:100
Ki67 Rabbit monoclonal, clone SP6 Cell Marque, Rockling, CA, USA 1:500
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and the secondary peroxidase labeled antibodies goat anti-
mouse or goat anti-rabbit (DakoCytomation K4002, Car-
pinteria, USA), visualized by 3-amino 9-ethyl-carbazole
(AEC) solution and hematoxylin counterstaining.
Assessment of tumor cell proliferation
Ki67 immunoreaction was evaluated using light micros-
copy at 2009 magnification by two independent observers
(review of discordant cases by a supervisor). Reactivity to
Ki67 was evaluated by semi-quantitative scoring consid-
ering the percentage of positive tumor area and the staining
intensity (grading: negative = 0, low = 1, moderate = 2
or strong = 3) [13]. The percentage of positive area was
multiplied by the grades leading to an overall scale from 0
(no positive cells) to up to 300 (100 % positive cells).
Different regions of interest were defined: non-necrotic
areas within the liver metastasis and representative areas in
the surrounding liver parenchyma; the latter was further
subdivided into the invasion zone (hepatic margin outside
the metastases) and hepatic areas distant from the metas-
tases. Seven to 10 fields of view were counted per region of
interest.
Relative quantification using RT-PCR analysis
For mRNA analysis, specimens from the entire liver were
collected and defrosted in peqGold TriFast (Peglab, Erlan-
gen, Germany) (1 ml/1 g tissue) and then homogenized
using the Ultra-Turrax (IKA, Bielefeld, Germany). Ten
microlitre of the mixture were then filled with 1 ml of
pegGold TriFast. Total RNA was isolated according to the
manufacturer’s instructions and stored at -80 C. First
strand cDNA was synthesized using an iScript cDNA
Synthesis Kit (BioRad, Munich, Germany) with oligo-(dT).
PCRs (Sso Fast EvaGreen Supermix, BioRad, Munich) were
carried out using an iCycler (BioRad, Munich, Germany)
with intron spanning primers (Eurofins MWG, Ebersberg,
Germany) (see Table 2), and reactions were normalized to
b2-microglobuline (b2-MG) and hypoxanthine–guanine
phosphoribosyltransferase (HPRT) as internal standards.
Amplification and expression analysis were performed as
recommended by the manufacturer. Quantitative real time
PCR was carried out at 30 s 95 C, 409 (denaturation 5 s
95 C, annealing/extension 5 s 55–60 C).
Magnetic resonance imaging (MRI)
MRI was used to monitor the growth of liver metastases
and to quantify overall tumor burden as well as whole liver
volumes 2 weeks following implantation of the CC531
tumor cells. Rats were anesthetized under constant sevo-
fluran inhalation and scanned in a 3T clinical MRI system
(Magnetom TIM Trio, Siemens Healthcare, Erlangen,
Germany) using an eight-channel receive coil designed for
the human wrist (Invivo Corporation, Gainesville, USA).
The examination comprised axial T2-weighted turbo-spin-
echo (TSE), diffusion-weighted (DW) echo-planar, and T1-
weighted gradient-echo MRI. Coronal TSE was used to
check for additional extrahepatic metastases. The intrahe-
patic tumor site was confirmed by loss of the DW signal.
The volumetric analysis was performed using OsiriX
(Pixmeo, Geneva, Switzerland). Whole liver and tumor
margins were manually outlined on each slice of T2w
sequences, taking advantage of the high natural contrast
between liver (containing iron with high T2 relaxivity and
CRC metastases with slower T2 relaxation). Volumes were
calculated manually.
Table 2 Primers for expression
studies
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Statistics
Results were expressed as mean ± standard error of the
mean (SEM). Differences between two groups were eval-
uated with the unpaired Student’s t test. Analysis of vari-
ance (ANOVA) was used to determine statistical
differences. A p value B0.05 was considered significant.
Results
Characterization of the CRC liver metastases
On macroscopic assessment, 85–90 % of animals devel-
oped liver metastases in any number of liver lobules during
the course of the study. However, there was an inhomo-
geneous spread of tumor burden, with tumors appearing in
general larger in size in the right-hand lobes of the liver.
On the microscopic level, the kinetics of metastatic growth
and phenotypic expression of markers were assessed by
immunofluorescence staining 3 days, 1 and 2 weeks fol-
lowing tumor cell implantation. CC531 cells readily
implanted into the liver plates and formed metastases
gradually increasing in size from small conglomerates
(3 days) to moderately sized metastases (1 week) and
subsequently large masses growing to confluence at the
endpoint of the experiment (2 weeks) (Figs. 1, 2). Liver
metastases intensively expressed the hyaluronic acid
receptor CD44 (putative marker of ‘stemness’ in CRC)
throughout the cytoplasm and cell membranes at all points
Fig. 1 Growth pattern and expression of characteristic tumor markers
in expanding CRC liver metastases. Immunohistochemistry and
multilayer immunofluorescence stainings for the characterization
3 days (3d), 1 week (1w) and 2 weeks (2w) following implantation of
CC531 via the portal vein in WAG/Rij rats. a Detection of CD44 to
visualize expanding CRC liver metastases which display a pushing
growth pattern, which is most evident at 2 weeks (see insert). The
surrounding hepatocytes are compressed and run in parallel forming
a ring-like border with the circumference of the metastasis.
b Co-localization of CD44 (red) as a surrogate parameter to visualize
the tumor burden (almost 100 % staining of tumor cells) and the
ductular marker CD49f (present in only 70 %) (green). c Co-locali-
zation of CD44 (red) and hepatic gap-junction protein Cx32 (green).
Loss of expression of the latter in hepatocytes found in close proximity
to the metastases 2 weeks post PH. FITC (red) and TRIC (green)
fluorescent channels are demonstrated separately and were overlaid in
the last column. Nuclear counterstaining with DAPI (blue), original
magnification 9200, scale bar = 20 lm. (Color figure online)
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in time of the experiment (Fig. 1). According to Vermeulen
and his workgroup, three different histological growth
patterns can be distinguished in human CRC liver metas-
tases: desmoplastic, pushing and replacement [14, 15]. In
the rat liver metastases, a ‘pushing’ growth pattern was
detected, with a characteristic liver margin in which
hepatocytes were ‘pushed’ aside, forming a ring-like bor-
der (margin) to the metastases at 2 weeks (Fig. 1a). At the
earlier points in time (3 days and 1 week), none of the
mentioned growth patterns was at all noticeable, as the
tumors at these points were still fairly small and limited.
Within the numerous metastases, we found an overall
homogeneous expression pattern of CD44 of approxi-
mately 100 % staining of all tumor cells. Of note, cytospins
from detached tumor cell suspensions (just prior to cell
implantation) also demonstrated a high degree of immu-
noreactivity to CD44 (data not shown). We therefore
considered CD44 as a suitable surrogate parameter when
tracking tumor cells in vivo. Approx. 70 % of the tumor
cells co-expressed the ductular marker CD49f (Fig. 1b). In
more detail, those differentiated subclones were arranged
in ductular structures and displayed intense staining of
CD49f, which was more or less extended over the outer cell
membranes.
To visualize the surrounding liver parenchyma, we
chose Cx32, a major component of the hepatic gap junction
protein, to depict functionally intact hepatocytes (Fig. 1c).
At earlier points in time (3 days and 1 week), the hepato-
cytes in close proximity to the liver metastases appeared
unharmed, as they displayed the regular dotted staining
pattern. However 2 weeks following tumor cell implanta-
tion, the liver metastases were surrounded by a small
margin of 2–4 hepatocyte layers, the cells of which
expressed Cx32 at a remarkably reduced level if at all. This
tumor-liver parenchyma interface corresponded to the
‘pushed’ margin as described above.
The majority of sporadic human CRC display a mutation
in the b-catenin dependent wnt-signaling, leading to
increased activity of the pathway. With reference to our rat
model of CRC liver metastases, we also detected vastly
membrane-bound and intense staining of the wnt-receptor
frizzled in approximately 50–60 % of tumor cells in forming
metastases (Fig. 2a) and a high degree of expression of
mostly cytosplasmatic b-catenin in 80–90 % at all investi-
gated points in time (Fig. 2b). Additionally, STAT3, an
oncogenic transcription factor, was also found to be con-
stitutively activated in these rat CRC liver metastases, as
demonstrated by the near-total (approx. 95 %) positive
nuclear staining (Fig. 2c). Owing to technical hindrances,
we were unable to co-stain b-catenin or STAT3 with CD44.
Assessment of tumor burden
MRI was used to locate the metastases and to measure
volumes of livers and metastases in the intervention group
(PH) and sham-OP group. In summary, MRI confirmed the
macroscopic results from animal autopsies: extrahepatic
metastasis was detected neither in the lungs nor peritoneal
cavity. Furthermore, metastasis was present predominantly
in the right liver lobules.
Two weeks following tumor cell implantation, the mean
total liver volume per animal was 1.3 times greater in the
PH group than in the sham-OP group (6.66 vs. 5.02 cm3,
p \ 0.03) (Fig. 3a). Representative coronal sections from
T2-weighted MRI displayed the intrahepatic high-contrast
tumor masses, which were evidently larger in size (as
Fig. 2 Activation of tumor signaling pathways (wnt and JAK/STAT) in
rat CRC liver metastases. a Co-localization of CD44 (red) and frizzled
(green). b Single staining of b-catenin (green). c Staining of the
transcription factor STAT3 (green). Nuclear counterstaining with DAPI
(blue). Time points as indicated (3d, 3 days; 1w, 1 week; 2w, 2 weeks).
Original magnification 9200, scale bar = 20 lm. (Color figure online)
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illustrated by their orthogonal diameters) after PH than
those from the sham-OP (Fig. 3b, c). More importantly, the
growth of metastases following PH exceeded the increase
in liver volume. The mean metastatic mass per animal was
calculated as 3.1 cm3 (PH) compared to 0.85 cm3 (sham-
OP) (p \ 0.01), representing a 3.6-fold increase in tumor
burden. Relative tumor mass (RTM), defined as (tumor
volume/total liver volume) * 100, was determined to be
45 % compared to the sham-OP group, in which the RTM
was only 16 % (p \ 0.01) (Fig. 3d). This corresponds to a
2.8-fold increase.
To confirm these volumetric results, the tumor burden
was additionally assessed by detecting CD44 gene
expression levels in homogenized rat livers. As seen in
Fig. 3e, PH provoked a significantly greater CD44
expression in tumor-bearing livers (p \ 0.03). The mRNA-
level was 2.3 times higher in the intervention group when
compared to the sham-OP group. It is worth noting that
livers in the control group had levels similar to those
exhibited by unharmed, normal liver.
Molecular composition CRC liver metastases
RT-PCR revealed changes in the molecular composition of
tumor-bearing livers following PH. The transcripts of
CD49f, CXCR4 and Axin2 were considerably elevated at
the endpoint (p \ 0.03). The receptor c-met demonstrated
a tendency to higher levels of expression in the PH group
(data not shown). The relative expression, defined as
individual marker gene expression/CD44 expression as a
representative of tumor burden and calculated for each
individual animal, did not prove to be statistically signifi-
cant enough to be able to differentiate between the PH and
sham-OP group for all 4 markers investigated (Fig. 4).
Fig. 3 Quantitative assessment of tumor burden and liver volumes
2 weeks following implantation of CC531 into rat livers. a MRI
volumetric quantification: absolute volumes of whole livers (grey)
and total metastatic volume (black): liver tissue volumes in PH-
treated animals increased 1.4 fold in contrast to sham-OP animals.
Total metastatic volumes following PH increased up to 3.6-fold in
contrast to sham-OP animals. T2-weighted MRI displaying represen-
tative coronal sections of rats: prominent and large tumor masses of
high contrast in the right liver lobules and only small unaffected
(‘non-metastatic’) liver margin after PH (b), sham-OP animals
revealed limited tumor growth (c); the diameters of tumor masses
are outlined by double-headed arrows. d Relative tumor mass (RTM)
following PH and sham-OP. Tumor burden increased 2.8-fold after
PH. e RT-PCR quantification of CD44 gene expression as an
surrogate parameter for the metastatic burden revealed a 2.3-fold
increase in CD44-transcripts in the PH group when compared to
sham-OP; normal livers (NL) and control (buffer ? PH) as indicated.
Significant levels as indicated. Data are mean ± SEM of 7–10
different animals per group and of three independent experiments
(RT-PCR)
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Assessment of proliferation in metastases
and surrounding liver
The expression of Ki67 was evaluated in the metastatic livers
by means of a semi-quantitative scoring procedure (Fig. 5).
Cell proliferation was determined to be significantly higher
in liver metastases following PH when compared to sham-
OP (mean score points 180 vs. 149, p \ 0.01).
Analysis of proliferation in the surrounding hepatic tis-
sue revealed moderate scores in both groups (PH and
sham-OP) for the two investigated regions of interest
(invasion zone = 26 vs. 25 score points and area distant to
the metastases = 50 vs. 42 score points). No statistical
significance ensued from the proliferation scores. However,
these scores were well comparable with the growth activity
of regenerating healthy livers (32 score points) found 24 h
after PH (considered as the ‘‘gold standard’’ when mea-
suring hepatic regenerative response).
Discussion
PH is considered as a favored treatment option for selected
patients with CRC liver metastasis. Even so, liver surgery
promotes hepatocytes into multiplication, leading to the
reconstitution of lost liver mass. However, this also results
in the release of numerous cytokines and growth factors as
well as the subsequent activation of multiple pathways, all
of which potentially contributing to the growth of residual
intrahepatic tumor cells or relatively cryptic satellite
metastases and disseminated circulating tumor cells [16].
Liver regeneration is a complex and well-orchestrated
process, during which molecular signals may exert dra-
matic as well as irreversible ‘side effects’ on tumor cells
stimulated into proliferation. We employed a rat model of
CRC liver metastases to investigate these mutual effects of
liver regeneration on the liver itself as well as on the
growth of implanted tumor cells.
The syngeneic colon carcinoma cell line CC531, origi-
nally derived from a 1,2-dimethylhydrazine-induced rat
colon adenocarcinoma, exhibits a reproducible growth
pattern and forms ever-increasing tumor masses following
intraportal injection into syngeneic WAG/Rij rats.
Although this model bypasses the natural evolution of
colon cancer, it produces macroscopic liver metastases
within 2 weeks after injection of CC531 in up to 85–90 %
of animals and is therefore a suitable model to study tumor
biology as well as the influence of hepatic regeneration on
tumor growth. We noted that the metastatic burden in our
rat model displayed a slight preference for the right liver
lobules following the chosen direct implantation route via
the portal vein. This discovery is interestingly in agreement
with findings in human liver, of which the right lobule
(Couinaud segments V–VIII) has proven to be the most
frequent site (63 % or relatively 67 %) of CRC liver
metastasis [17, 18].
Fig. 4 Relative expression of
tumor markers correlated to
tumor burden (gene levels of
homogenized livers were related
to the gene expression of
CD44). Data are mean ± SEM
of 7–10 different animals
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Constitutional expression of cell surface markers
and activation of tumor signaling pathways in liver
metastases from CC531
To investigate characteristic CRC features, an experimen-
tal model mimicking the situation observed in humans is
mandatory. We therefore investigated the expression of
specific cell surface markers such as CD44 and CD49f in
the rat liver metastases. High levels of CD44 expression
were demonstrated in the tumors deriving from CC531.
This trans-membrane glycoprotein is known to be involved
in tumor formation and invasion, cell adhesion and cell
migration and it is typically over-expressed in colorectal
tumors as opposed to normal mucosa [19]. CD44 is also
attributed to distinct ‘stemness’ features in CRC with
additional properties such as high mitotic capability, col-
ony formation and drug resistance to conventional
chemotherapies [20, 21]. In our study, we also observed
rapid tumor growth following implantation of CC531,
suggesting that such extensive expression of CD44 in vivo
is one feature demonstrating the ‘aggressive’ phenotype of
this cell line. However, we have to consider other factors
and molecules that could be also involved in the aggressive
behavior. As almost all tumor cells are immunoreactive to
CD44, we chose this marker as a suitable surrogate
parameter to track tumor cells microscopically and to
investigate tumor burden on the molecular level (tran-
scripts). Another typical cell surface marker (CD49f = a6
integrin) of CRC was only expressed in some ductular
subclones of the rat liver metastases. Integrins play a piv-
otal role in normal and diseased intestine, as they are
responsible for the mediation of cell–matrix interactions
such as the specific ligation of various macromolecules
(laminins, fibronectins and tenascins) [22]. For example,
integrin a5/b1 expression is frequently lost in CRC cells
when compared with normal intestinal epithelium; colon
cancer cells lacking this integrin are renowned for their
extraordinarily proliferative capacity and tumorigenicity
[23]. Here in our studies, liver metastases from CC531
were negative for CD49f to an extent of 30 %, suggesting
this as a criterion for a profound metastatic cancer cell line.
We also investigated parameters of two representative
tumor signaling pathways (wnt and JAK/STAT), which are
known to be altered in human CRC. Wnt-Signaling plays
an important role in the formation of CRC and efforts to
explore therapies designed to target this pathway are in the
focus of many research groups [24]. In our study, forming
liver metastases from CC531 demonstrated membrane-
bound expression of the frizzled-receptor as well as intense
cytoplasmatic expression of b-catenin. Both markers may
represent the constitutive activation of the wnt-pathway in
our rat model. Furthermore, STAT3 is aberrantly activated
in human CRC tissue and found to correlate to malignant
tumor progression through the up-regulated expression of
matrix metalloproteinases [25, 26]. In our study, we also
demonstrated high nuclear expression in liver metastases
derived from CC531.
In summary, we demonstrate that our experimental
model is not only feasible and reproducible, but also
mimics well observations in humans and could therefore be
considered as a suitable pre-clinical rat animal model for
the further study of the behavior of orthotopic CRC liver
metastases following the stimulus of PH.
Proliferation of liver metastases and effects
on the surrounding liver tissue following PH
The hepatic regeneration process is triggered promptly
after injury. In rats, DNA replication begins as early as
16 h after PH [27]. Between 5 and 7 days, the liver volume
is almost completely restored (approx. 98 %) through
hyperplasia of the remaining lobes [16]. However, even
after complete recovery of the total organ mass, the
regeneration and remodeling process may continue. At the
Fig. 5 Assessment of cell proliferation by semi-quantitative scoring
of Ki67 staining. a CRC liver metastases demonstrated high Ki67
scores following PH (vs. sham-OP), p \ 0.001. b Moderate prolif-
eration scores of hepatocytes in the surrounding liver tissue in close
proximity to metastases (invasion zone) and in distance to the
metastases; additional control for comparison = healthy and regen-
erating liver at 24 h after PH. Data are mean ± SEM of 7–10
different enumerations of the fields of view per region of interest.
Significance level as indicated
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endpoint in our studies (2 weeks following injection of
CC531), we observed ongoing DNA synthesis, as illus-
trated by the marked immunoreactivity to Ki67 in liver
metastases in both groups, significantly more so in the PH
group on direct comparison. It is worth noting that sub-
stantially elevated Ki67 scores were also detected in the
surrounding liver parenchyma, which may also suggest
continued cell proliferation through presumably paracrine
or space-requiring effects as a result of the stimulated
expansion of metastatic tissue towards the end or even after
termination of liver regeneration (10–14 days following
PH). In accordance, Harun et al. [28] also detected long-
lasting and significantly greater numbers of proliferating
tumor cells as a function of the extent of liver resection as
late as on day 21 following PH (37 and 70 %).
Histological analysis revealed a ‘pushing’ growth pat-
tern of rat CRC liver metastases. They certainly appear to
exert a relevant effect on the surrounding liver plate,
leading to this characteristic re-arrangement of adjacent
hepatocytes. Of note, this histological pattern is most fre-
quent (approx. 35 %) in human CRC liver metastases and
was found to be an independent predictor of poor survival
(at 2 years follow-up) suggesting the more aggressive
tumor biology behind this phenomenon [15]. Cx32 has
been studied to investigate the ‘gap function’ and mainte-
nance of tissue homeostasis in the liver and it plays an
important role in monitoring the loss of functionality dur-
ing the course of liver disease [29]. In our studies, we also
observed a loss of this hepatic marker in the tumor-liver
parenchyma interface of 2–4 hepatocyte layers in direct
proximity to the liver metastases. In accordance to the
observed ‘pushing’ growth pattern, this impairment of cell
integrity in hepatocytes (‘pushed’ liver margin) underlines
the profound impact exerted by tumor cell growth on the
surrounding liver tissue.
Evaluation strategies and PH as a significant impact
on tumor growth
Several studies have already investigated the stimulatory
effects of PH on liver metastases in the past [28, 30–34].
Most commonly, wet liver weight, macroscopic assessment
or histological analysis methods were used to measure the
hepatic tumor burden with obvious limitations for the exact
evaluation of the morphometric data. In our study, we
employed MRI T2-weighted images to evaluate tumor
growth in all liver lobules as well as in extrahepatic sites.
Over nearly a decade, MRI has emerged as the gold stan-
dard imaging technique in the detection and characteriza-
tion of liver lesions owing to its high specificity resulting
from optimal lesion-to-liver contrast and lack of ionizing
radiation [35]. The implementation of this non-invasive,
high-resolution imaging modality enabled us to calculate
and quantify the extent of the hepatic tumor burden in our
pre-clinical rat model to a much greater degree of accuracy.
In more detail, we demonstrated that 1/3 PH was well
associated with a volumetric increase by a factor of nearly
3 (2.8-fold) in the RTM. Our MRI results were confirmed
on the molecular level, as we found similar results, such as
a 2.3-fold amplification in gene expression of CD44—the
surrogate marker for tumor burden in our studies.
We believe it is important to reiterate at this point that
PH was performed 24 h following implantation of CC531.
Thus, anything up to 30 % of the CC531 cells were
removed through PH. As a direct result of this technically
unavoidable loss, the initial tumor cell load was always
lower in the PH group. Even so, we still detected a sig-
nificant increase in tumor burden after 2 weeks. Since we
were unable to determine numbers of CC531 cells lost to
PH, this was not taken into account when comparing and
contrasting the PH group with the sham-OP group.
We would like to add that we specifically used an
immunocompetent animal model with syngeneic and
orthotopic implantation of CRC tumor cells to produce
liver metastases, aiming to be as close to the clinical sit-
uation as possible and taking into account the very
important role of tumor cell growth in the presence of an
intact immune system [36]. Many (if not most) other ani-
mal models use heterotopic implantation sites (e.g. limbs)
to simplify the process of tracking the fate of tumor cell
growth. These methods often employ direct sight and/or
vector imaging technologies based on the insertion of a
reporter gene (e.g. red fluorescent dye) into the cancer cell
lines, emitting in the near-infrared spectrum for non-inva-
sive, high-resolution and life-time detection in the tissue
[37, 38]. However, these fluorescence-labeling gene
delivery systems are predominantly used in nude (immu-
nodeficient) mice. The insertion of a fluorescent protein tag
is immensely capable of activating the host immune sys-
tem, leading to the complete elimination of engrafted
labeled tumor cells (own observation following stable
transfection of the red fluorescent marker mCherry into
CC531). In contrast, we were able to perform native MRI
scans without any need to employ potentially immunogenic
or harmful substances (proteins, antibodies, viral vectors)
to mediate the imaging.
When considering the effects of PH on the growth of
liver metastases in animal models, a number of studies
have determined that the extent of hepatic resection is
associated with a higher incidence and volume of tumor
recurrence [39, 40]. The direct correlation between PH and
the stimulatory effect on tumor growth was also demon-
strated by Panis et al. [41, 42]. Colon carcinoma cells
(DHD K12) were injected into the portal vein of BD IX rats
and only 40 % of animals had developed liver metastases
within 8 weeks. However, when 2/3 PH was performed, the
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incidence of liver metastases increased to 62 %. It appears
most likely that liver micrometastases were present, but did
not begin development until stimulated by liver regenera-
tion. Slooter et al. [31] revealed that PH significantly
increased the number of liver metastases following PH and
successfully used a concept of adjuvant treatment with
TNF-a to reduce the number of outgrowing metastases.
However, Harun et al. [28] could only confirm a significant
stimulatory effect on tumor growth if the mice underwent a
large 2/3 PH and the CRC cells were implanted at a rela-
tively late stage in liver regeneration (on day 6 post PH). In
comparison, only a very few studies have shown that minor
resection of less than 50 % did not result in tumor stimu-
lation [43, 44]. In contrast, our own work demonstrates that
1/3 PH is more than able to exert a proliferative effect on
CRC liver metastases, suggesting that there is indeed no
clear threshold below which tumor cells are no longer
stimulated. However, tumor cell engraftment and the out-
growth of metastases may very much depend on the
number of cells implanted as well as the type of cancer cell
line as basis.
The differences in liver volume increase and metastatic
burden following PH or sham-OP was clearly demonstrated
by MRI. However, since we used clinical MRI hardware
and conventional MRI contrast, we may have underesti-
mated the entire tumor burden by missing out small
metastases and satellite tumors in the liver parenchyma due
to the limited resolution (1 mm slices of 0.33 mm). We
will therefore employ gadolinium-based contrast agents in
our future MRI studies, as this change in protocol may
further enhance the demarcation of the tumor masses in the
liver [45, 46]. This change may be key in the assessment of
limited tumor growth, especially at earlier points in time
following implantation, either during the initial phase
(1–3 days following PH) or the ongoing course of liver
regeneration (within 5–7 days). Of note, we will employ
the gadolinium-based contrast agent gadobutrol (Gadovist/
Gadavist, Bayer Pharma AG, Berlin, Germany) in a non-
toxic chelated preparation which exhibits negligible protein
binding, distributes in extracellular space only, and is
rapidly excreted via the renal pathway. It is widely used in
humans to detect hepatic lesions or liver metastases
respectively and well tolerated following intravenous
injection either of a diagnostic single or repeated doses,
with no relevant toxicity to the liver in either humans or
rodents [47–49].
Evaluation of molecular changes in CRC liver
metastases following PH
We investigated the molecular features in homogenates
from tumor-bearing livers, presuming that the transcript
levels of the molecular markers Axin2, CXCR4, CD49f and
c-met were predominantly attributed to the metastatic bur-
den, as they were barely detectable in normal livers or in
livers from control animals. We considered a panel of
markers for the investigation of specific tumor characteris-
tics, aspects of invasiveness and aggressiveness, all known
to promote tumor cell growth in the liver parenchyma:
Axin2 is well known as an important target gene of the
canonical wnt-signaling cascade constitutively activated in
CRC [50]. The chemokine receptor CXCR4 contributes to
tumor growth and the metastatic spread of several cancer
entities [51]. CD49f, as mentioned above, was chosen as an
essential ligand for tumor cell adhesion. Hepatocyte growth
factor (HGF) is a key player during the proliferation phase of
liver regeneration and synergistically acts in tumor pro-
gression. Its high-affinity receptor c-met is frequently
amplified or over-expressed in CRC and high expression
levels are associated with cancer progression, metastatic
growth and invasiveness [52]. Surprisingly, we were unable
to detect any changes in the relative mRNA expression
levels of the molecular markers in metastatic liver following
PH. This may suggest that the stimulus derived from liver
regeneration acted on the CC531 cells in a uniform fashion
to increase the metastatic mass, but did not result in any
preferential stimulation of individual subclones.
Conclusion and therapeutic implications
Liver regeneration is arguably the most fascinating and
complex regenerative response to injury. It follows an
intricate network of cytokines and cell-growth factors
mediating the restoration of liver function and morphology
[53]. However, there is mounting clinical evidence that
liver regeneration can be both beneficial and detrimental,
depending on the nature of the cell responding to the
proliferation stimulus [54].
It is important to recognize the limitations of our rat
model of CRC liver metastasis as a pre-clinical research
environment. Firstly, this animal model will never
approach the complexity of the human situation of
continuing tumor development and formation of metasta-
sis. Secondly, PH was actually performed in active tumor
disease (liver resection 24 h following tumor cell implan-
tation). However, the present study was specifically
designed to identify the extent of 1/3 PH as a stimulatory
effect on the growth of CRC rat liver metastases and on
their molecular composition. Both issues were examined in
this rat animal model with clear results. Furthermore, our
present work may serve as a pilot study for more detailed
investigations addressing the fundamental questions as to
whether the molecular and cellular mechanisms of tumor
cell growth are related to the three different phases of liver
regeneration (1: priming (ECM degradation), 2: prolifera-
tion (DNA synthesis) and 3: termination (ECM remodeling
Clin Exp Metastasis (2013) 30:681–693 691
123
and angiogenesis)). It has been suggested that molecules
regulating the late phase of liver regeneration may be the
key factors in tumor cell growth and disease progression
[54]. Thus, future studies need to determine possible tar-
gets and therapeutic applications as to how to hinder the
natural liver regeneration response at least in part in such a
manner without any acute detriment, in order to effect the
necessary regenerative response of a liver already impaired
in a likely clinical setting of multimodal treatment concepts
following neo-adjuvant chemotherapy and/or post-opera-
tive adjuvant systemic therapy [55].
It is worth mentioning that de Jong et al. [56, 57] provided
a proof of principle that radioimmunotherapy using a radi-
olabeled monoclonal antibody was effective in the treatment
of at least microscopic liver metastases and was additionally
effective in an adjuvant treatment modality after surgery.
When referring to larger CRC metastases, cell-cycle-
blocking agents such as ionizing radiation could be con-
sidered not only to eliminate the liver metastases them-
selves, but also to reduce the regenerative response of the
surrounding liver mass as a method of pre-treatment prior to
liver resection. For example, external-beam and partial liver
irradiation may prove promising in this difficult multidis-
ciplinary approach, as the dose of radiation can be adjusted
and precisely targeted to parts of the liver [55, 58]. No doubt,
future studies will be necessary to clarify the underlying
mechanisms, treatment options and understanding of CRC
metastatic recurrence in regenerating liver.
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